Protocol Ledger

NCT03509961 · Phase II · RECRUITING

The EndRAD Trial: Eliminating Total Body Irradiation (TBI) for NGS-MRD Negative Children, Adolescents, and Young Adults With B-ALL

Interventional Phase II clinical trial protocol NCT03509961 sponsored by Pediatric Transplantation & Cellular Therapy Consortium in Oncology and Hematology, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2018-08-29 Enrollment: 95 participants (ESTIMATED) Federal Source: clinicaltrials.gov/study/NCT03509961
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)95 participants (ESTIMATED)
Disclosed U.S. Hospital Campuses vs Median (6 sites)4 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT03509961
Protocol FieldVerified Registry Value
NCT IdentifierNCT03509961
Consolidated Lead SponsorPediatric Transplantation & Cellular Therapy Consortium
Therapeutic Condition CohortOncology and Hematology
Clinical Trial PhasePhase II
Overall Recruitment StatusRECRUITING
Registered Enrollment95 participants (ESTIMATED)
Registered Start Date2018-08-29
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Search related sites and sponsors in the Interactive Directory, explore Oncology and Hematology Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI